Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anchor Therapeutics has concluded the first phase of its collaboration and licensing pact with Ortho-McNeil-Janssen Pharmaceuticals (OMJPI), under which both the companies have worked to jointly discover and optimize preclinical development candidates against GPCR targets in oncology and metabolic disorders.
Subscribe to our email newsletter
The achievement represents progress for the collaboration, which was launched in September 2010 to develop G protein coupled receptor (GPCR)-targeted therapeutic compounds utilizing Anchor’s proprietary pepducin technology.
Pepducins are lipidated peptides designed to be allosteric modulators for G protein coupled receptor (GPCR) targets, especially those intractable to current approaches.
During this initial research phase, Anchor pepducins demonstrated to have in-vivo efficacy in a relevant model and satisfactorily achieved other criteria necessary to earn further research funding support.
Anchor said that these results triggered an undisclosed cash payment to Anchor.